Access on ReachMD
Access on PACE-CME
← Back to Learning Center
Clinical Practice
Efficacy and Safety of Finerenone in Patients With Non-Diabetic CKD: Insight From FIND-CKD
Clinical Practice
Finerenone Efficacy and Safety in Patients With CKD Regardless of Diabetes Status: Insights From the INFINITY Dataset
Clinical Practice
Finerenone Subgroup Analyses in Patients With Glomerulonephritis
CME/CE
Finerenone in HFpEF: Key Insights From ESC HF
CME/CE
Treatment Patterns and MRA Use in Patients with HFmrEF/HFpEF: Insights From FRAME-HF and IRIS HF
CME/CE
SPIRIT-HF: Does Spironolactone Improve Outcomes in HFpEF and HFmrEF?
CME/CE
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
CME/CE
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
CME/CE
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
CME/CE
The Fifth Pillar? Closing the Gap in HFrEF
CME/CE
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
CME/CE
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum
CME/CE
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
CME/CE
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
CME/CE
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
CME/CE
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
CME/CE
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
CME/CE
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
CME/CE
VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
CME/CE
Effect of Vericiguat on Heart Failure Hospitalization Events in Ambulatory Patients With HFrEF: VICTOR Trial Prespecified Analysis
CME/CE
Optimizing Patient Outcomes in CKD & T2D Care With CONFIDENCE
CME/CE
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
CME/CE
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40%
CME/CE
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
CME/CE
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
CME/CE
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
CME/CE
Topline Results of the CONFIDENCE Trial
CME/CE
Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
CME/CE
Albuminuria Change and Finerenone's Effect on CV Outcomes
CME/CE
The CONFIDENCE Trial: Data Insights
CME/CE
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
CME/CE
Shifting Treatment Paradigm in HFmrEF/HFpEF: Steroidal and Nonsteroidal MRAs
CME/CE
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
CME/CE
Novel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
CME/CE
FINEARTS-HF Analysis of Patients With HFmrEF/HFpEF Both With and Without AF
CME/CE
Effect of Finerenone on NT-proBNP in the FINEARTS-HF Trial
CME/CE
Kidney Risk Stratification in the FINEARTS-HF Trial
CME/CE
FINE-HEART Pooled Analysis
CME/CE
Mode of Death in Patients With HFmrEF/HFpEF From FINEARTS-HF
CME/CE
FINEARTS-HF Analysis Based on NYHA Functional Class
MinuteCE
®
Bridging the Gap: ns-MRAs in Cardiovascular-Kidney-Metabolic Syndrome Care
MinuteCE
®
Optimizing Care for Patients With CKM Syndrome: A Multidisciplinary Approach
CME/CE
Expert Panel New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
No result - please try back later!
This curriculum is provided by Medcon International, Inc.
Funding for this educational program was provided by an unrestricted educational grant from Bayer AG.
